Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation

Journal of Arrhythmia

Volumn 32, Issue 1, 2016, Pages 42-50

  Ikeda, Kozue ^a   Tachibana, Hideaki ^a  

^a Shinoda General Hospital   (Japan)

Author keywords

Anti factor Xa activity; Atrial fibrillation; Chromogenic assay; Direct factor Xa inhibitor

Indexed keywords

EID: 84958174105     PISSN: 18804276     EISSN: 18832148     Source Type: Journal    
DOI: 10.1016/j.joa.2015.08.001     Document Type: Article

References (19)

1. M.M. Samama, J.L. Martinoli, L. LeFlem, and et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
2. M.M. Samama, J. Amiral, C. Guinet, and et al. An optimized, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma Thromb Haemost 104 2010 1078 1079
3. J. Harenberg, R. Krämer, C. Giese, and et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability J Thromb Thrombol 32 2011 267 271
4. J. Douxfils, F. Mullier, C. Loosen, and et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature Thromb Res 130 2012 956 966
5. J. Douxfils, C. Chatelain, B. Chatelain, and et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide Thromb Haemost 110 2013 283 294
6. C. Frost, Y. Song, Y.C. Barrett, and et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban Clin Pharmacol 6 2014 179 187
7. Y.C. Barrett, Z. Wang, C. Frost, and et al. Clinical Laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Thromb Haemost 104 2010 1263 1271
8. T. Okada, K. Toyoda, A. Okamoto, and et al. Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan PLoS One 9 11 2014 e113641 10.1371/journal.pone.0113641 eCollection 2014
9. Gabbeta J, Krougliak V, Quiazon E, et al. Liquid Heparin assay: rapid monitoring of clinically used heparins. In: XXI Congress of the International Society on Thrombosis and Haemostasis; July 2007.
10. Krougliak V, Gabetta J, Kung C, et al. Monitoring direct and indirect factor Xa inhibitors with a new Liquid Heparin assay. In: The 21st International Congress on Thrombosis; July 2010.
11. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
12. M. Hori, M. Matsumoto, N. Tanahashi, and et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study Circ J 76 2012 2104 2111
13. C.B. Granger, J.H. Alexander, J.J.V. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
14. S. Owgawa, Y. Shinohara, and K. Kanmuri Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation: the ARISTOTLE-J study Circ J 75 2011 1852 1859
15. Xarelto gaiyo. 2014 March version. Osaka: Bayer Yakuhin, Ltd.; 2014, 33-4. (http://www.bayer-hv.jp/hv/files/pdf.php/140311-XAR-14-gaiyo-201403.pdf?id=1039e591f60472d3542ebbe71e3a0fc).
16. Eliquis interview form. Tokyo: Bristol-Myers Squibb, and Tokyo: Pfizer Japan Inc., 2015; 37-9. (http://file.bmshealthcare.jp/bmshealthcare/pdf/interview/IF-EQ1502.pdf).
17. A. Cuker, D.M. Siegal, M.A. Crowther, and et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants J Am Coll Cardiol 64 2014 1128 1139
18. M. Jun, M.T. James, B.J. Manns, and et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study Br Med J 350 2015 h246 10.1136/bmj.h246
19. Xarelto (Rivaroxaban Film-Coated Oral Tablets) Drug Information. RxList: (http://www.rxlist.com/script/main/hp.asp).